CIRRUCULUM VITAE

DAVID JOHNSON, MD

Licensure
Diplomate, American Board of Ophthalmology, November 1990
Diplomate, National Board of Medical Examiners, July 1986
Colorado State Board of Medical Examiners, October 1986

Current Position
Private Practice-Consulting Surgeon for Vitreoretinal Disorders

Academic Appointments
Associate Clinical Professor of Ophthalmology
University of Colorado School of Medicine, Denver, CO
September 2003-2012

Assistant Clinical Professor of Ophthalmology
University of Colorado School of Medicine, Denver, CO
July 1998-August 2003

Assistant Professor of Ophthalmology
University of Colorado School of Medicine, Denver, CO
July 1992-June 1998

Instructor of Ophthalmology
University of Colorado School of Medicine, Denver, CO
July 1989-July 1992

Chief, Division of Ophthalmology
Denver Health Medical Center
July 1989-June 1991

Postgraduate Training
Fellowship in Vitreoretinal Disease
Preceptor: Kenneth R. Hovland, M.D.
University of Colorado Health Sciences Center, Denver, CO
July 1991-June 1992

Residency in Ophthalmology
University of Colorado Health Sciences Center, Denver, CO
July 1986-June 1989

Transitional Internship
Presbyterian/Saint Luke's Medical Center, Denver, CO

June 1985-June 1986

Education
Doctor of Medicine
University of Louisville School of Medicine, Louisville, KY
May 1985, Magna Cum Laude

Bachelor of Arts
Transylvania University, Lexington, KY
May 1981, Summa Cum Laude

Professional Societies
- Fellow, American Academy of Ophthalmology
  Director, Leadership Development Program 2008-2012
  Secretariat for State Affairs Committee Member 2005-2009
  Leadership Development Program 2002-2003
  OPHTHPAC Committee Member 2016-present
- Colorado Society of Eye Physicians and Surgeons
  Advocacy Committee-Chair 2013-present
  Councilor to American Academy of Ophthalmology 2003-2011
  President 2002-2003
  Treasurer 2000-2002
  Chairman, Program Committee 1999-2010
  Member, Program Committee 1995-2010
  Medicare Carrier Advisory Committee Member 2004-present
- The American Society of Retina Specialists
- Pan-American Association of Ophthalmology
- Alpha Omega Alpha
- Colorado Medical Society
- Denver Medical Society

Publications
Peer-Reviewed Journals
Johnson, S.C., Benson, C.A., Johnson, D.W., Weinberg, A. Recurrences of Cytomegalovirus Retinitis in a Human Immunodeficiency Virus-Infected Patient, Despite Potent Antiretroviral Therapy and Apparent Immune Reconstitution. Clinical Infectious Diseases 2001 Mar; 32: 815-19.

Johnson, D.W., Cagnoni, P., Schossau, T., et al. Optic Disc and Retinal Microvasculopathy After High Dose Chemotherapy and Autologous Hematopoeitic Progenitor Cell Support. Bone Marrow Transplant 1999 Oct; 24 (7): 785-92.

Johnson, D.W. Fomivirsen: Viewpoints. Drugs 1999 Mar; 57 (3): 381.

Das, A., McGuire, P.G.,…Johnson, D.W. Human Diabetic Neovascular Membranes Contain High Levels of Urokinase and Metalloproteinases Enzymes. Investigative Ophthalmology and Visual Sciences 1999 Mar; 40 (3): 809-813.

Estacio, R.O., McFarling, E., Biggerstaff, S., Jeffers, B.W., Johnson, D.W., Schrier, R.W. Overt Albuminuria Predicts Diabetic Retinopathy in Hispanics with NIDDM. American Journal of Kidney Diseases 1998 Jun; 31 (6): 947-953.
Akler, M., Johnson, D., Burman, W., Johnson, S. Anterior Uveitis and Hypotony Following Intravenous Cidofovir For Treatment of Cytomegalovirus Retinitis. Ophthalmology 1998 Apr; 105 (4): 651-657.

Tudor, S., Hamman, R.F., Baron, A., Johnson, D.W., Shetterley, S.M. Incidence and Progression of Diabetic Retinopathy In Hispanics and Non-Hispanic Whites with Type 2 Diabetes. Diabetes Care 1998 Jan; (21):53-61.

Ferreira, R.C., Shea, C., Johnson, D.W., Bateman, J.B. ERG in Incontinentia Pigmenti. Journal of Pediatric Ophthalmology and Strabismus 1997 Sept; (1):172-4.

Taravella, M.J., Johnson D.W., et.al. Infectious Scleritis Caused by Pseudoallescheria Boydii: Clinicopathologic Findings. Ophthalmology 1997 Aug; 104 (8):1312-1316.

As Participant in COMS Study Group
COMS Study Group. Histopathologic Characteristics of Uveal Melanomas in Eyes Enucleated From the Collaborative Ocular Melanoma Study. COMS Report No. 6. American Journal of Ophthalmology 1998; 125: 745-766.

COMS Study Group. The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-Enucleation Radiation of Large Choroidal Melanoma I: Characteristics of Patients Enrolled and Not Enrolled. COMS Report No. 9. American Journal of Ophthalmology 1998; 125: 767-778.

COMS Study Group. The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-Enucleation Radiation of Large Choroidal Melanoma II: Initial Mortality Findings. COMS Report No. 10. American Journal of Ophthalmology 1998; 125: 779-96.

As Participant in The Vitravene Study Group
The Vitravene Study Group. A Randomized Controlled Clinical Trial of Intravitreous Fomivirsen for Treatment of Newly Diagnosed Peripheral Cytomegalovirus Retinitis in Patients With AIDS. American Journal of Ophthalmology 2002; 133: 467-474.

The Vitravene Study Group. Safety of Intravitreous Fomivirsen for Treatment of Cytomegalovirus Retinitis in Patients With AIDS. American Journal of Ophthalmology 2002; 133: 484-498.

As Participant in The Endophthalmitis-Ganciclovir Implant Study Group
Shane, T. S. and Martin, D.M. for the Endophthalmitis-Ganciclovir implant Study Group. Endophthalmitis After Ganciclovir Implant in Patients With AIDS and Cytomegalovirus Retinitis. American Journal of Ophthalmology 2003; 136: 649-654.

Abstracts
Johnson, D.W., Muccioli, C, Goldstein, D.A., et al. Safety and Efficacy of Fomivirsen in the Treatment of CMV Retinitis: A Phase 3, Controlled, Multicenter Study Comparing Immediate Versus Delayed Treatment. 8th International Congress on Infectious Diseases: 1998 May 15-18: Boston, 135.

Akler, M., Johnson, D., Burman, W. Anterior Uveitis Following Intravenous Cidofovir for the Treatment of Cytomegalovirus Retinitis. Ophthalmology Vol. 104, no. 9A, September 1997 supplement, 205.

Boyer, D., Lieberman, R., Antoszyk, A.,...Johnson, D.,... et al. Clinical Efficacy and Safety of Fomivirsen Sodium for the Treatment of CMV Retinitis Unresponsive to Other Antiviral Therapies. Ophthalmology Vol. 104, no 9A, September 1997 supplement, 206.

Lieberman, R., Antoszyk, A., Boyer, D., Danis, R., Duker, J., Fish, R., Goldstein, D., Johnson, D., Kupperman, B., Lambert, M., Mansour, S., Palestine, A., Park, S., Terry, B., Vrabec, T. Antisense Oligonucleotide (Fomivirsen Sodium) Treatment of CMV Retinitis Unresponsive to Other Antiviral Therapies. Investigative Ophthalmology & Visual Science Vol. 38, No. 4, S914.

Shea, C.J., Ferreira, R.C., Johnson, D. and Bateman, J.B. ERG in Incontenitia Pigmenti. Investigative Ophthalmology & Visual Science Vol. 38, No. 4, S880.

Kleinman, D.M., Zhang, K., Johnson, D.W. A Sensitive and Specific Polymerase Chain Reaction-Based Assay for Cytomegalovirus DNA in Aqueous Humor. Ophthalmology Vol. 103, no. 9A, September 1996 supplement, 188.

Johnson, D.W., Cagnoni, P., Schossau, T., et al. Optic Disc and Retinal Microvasculopathy After High Dose Chemotherapy and Autologous Hematopoeitic Progenitor Cell Support. Ophthalmology Vol.102, no. 9A, September 1995 supplement, 94.

Arnold, P.A. and Johnson, D.W. Characteristics and Visual Outcome of Cytomegalovirus Retinitis. Ophthalmology Vol. 99, no. 9A, September 1992 supplement, 114.

Johnson, D.W. and Hovland, K.R. Concentric Folds as a Sign of Metastatic Choroidal Tumors. Ophthalmology Vol. 99, no. 9A, September 1992 supplement, 139.

Book Chapters
Johnson, D.W. and Ellis, P.P. "Intraocular Foreign Body-Steel or Iron (Siderosis)" in Fraunfelder, F.T. and Roy, F.H.,ed., Current Ocular Therapy 5 W.B. Saunders Co., Philadelphia 1999.

Kleinman, D.M., Johnson, D.W., Braverman, J.M. "The Eye and Orbit" in Jafek, B.W. and Stark, A.K ed., ENT Secrets Hanley & Belfus, Philadelphia 1996.

Johnson, D.W. and Ellis, P.P. "Intraocular Foreign Body-Steel or Iron (Siderosis)" in Fraunfelder, F.T. and Roy, F.H.,ed., Current Ocular Therapy 4 W.B. Saunders Co., Philadelphia 1995.

Peer Reviewer-Journals
American Journal of Ophthalmology 2002
Child Abuse and Neglect 1994
Ophthalmology 1992

Research Projects
- Sub-Investigator: EYEGUARD™-A: A Randomized, Double-masked, Placebo-Controlled study of the Safety and Efficacy of Gevokizumab in the treatment of Active non-infectious Intermediate, Posterior, or Pan-Uveitis 2013-present.

- Sub-Investigator: EYEGUARD™-C: A Randomized, Double-masked, Placebo-Controlled study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis Currently controlled with Systemic Treatment. 2013-present.

- Sub-Investigator: Optina™ : A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of two Doses of Oral Optina™ in Adult Patients with Diabetic Macular Edema 2013-present.

- Sub-Investigator: STOP : Study of the Safety, Tolerability, and Bioactivity of Tocilizumab on Patients with Non-Infectious Uveitis. (Genetech) 2012-present.

- Sub-Investigator: BAM: A phase II, Multi-Center, randomized, double-masked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) 2012-present.

- Sub-Investigator: TOGA: A Randomized, Double-Masked, Placebo-Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary

to Non-Exudative Age-Related Macular Degeneration, University of Virginia. 2014.

- Sub-Investigator: VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW I), Regeneron 2008-2012.

- Sub-Investigator: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Injection-Controlled study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant macular edema with Center Involvement secondary to Diabetes Mellitus 2007-2011 (Genetech).

- Sub-Investgator: DNA Repository Substudy in Association with Ranibizumab Study FBF4579g: A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab administered monthly or on an as needed basis (prn) with a Safety Run-In of a Single Dose of 2.0 mg Ranibizumab in Patients with subfoveal neovascular Age-Related Macular Degeneration (Genetech) 2009-2011.

- Sub-Investigator: A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 ug/day and ASI-001B 0.2 ug/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injections in Subjects with Diabetic Macular Edema 2009-2011.

- Sub-Investigator:.AREDS II – Age-related Eye Disease Study II (AREDS II): A multi-center, randomized trial of lutein, zeaxanthin and omega-3 fatty acid in age related macular degeneration.

- Sub-investigator: Posurdex (Allergan) - A Phase 2, Multicenter, Masked, Randomized, Sham-Controlled 12-Month Trial (Plus a 12-Month Masked Extension) to Assess the Safety and Efficacy of a 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System as Adjunctive Therapy to Photodynamic Therapy with Verteporfin (PDT) in the Treatment of Patients with Age-Related Macular Degeneration (ARMD).

- Sub-Investigator: DENALI (Novartis) - A 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with ranibizumab (Lucentis™) versus ranibizumab (Lucentis™) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

- Sub-investigator: LEVEL (Eyetech) - Protocol EOP1023: A Phase IV, open label, multi-center, trial of maintenance intravitreous injections of Macugen (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with

subfoveal neovascular Age-Related Macular Degeneration (AMD) initially treated with a modality resulting in maculopathy improvement.

- Sub-investigator: BRAVO (Genentech) - FVF4165g: A Phase II multicenter, randomized sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion.

- Sub-investigator: CRUISE (Genentech) - FVF4166g: A Phase III multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion.

- Sub-Investigator: Novartis CRAD01A2203 - A randomized, double-masked, parallel group study to assess the efficacy of oral Everolimus 5 mg once daily, either alone or added to Lucentis, in patients with neovascular age-related macular degeneration.

- Sub-Investigator: HORIZON – FVF3426g – An Open Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) who have Completed a Genentech-sponsored Ranibizumab Study.

- Sub Investigator: Brimonidine (Allergan) DDS Optic Neuropathy Study (190342-030D). A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 6-Month (Plus 6-Month Extension) Study to Evaluate the Safety and Effects on Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS®) Applicator System in Subjects with Primary Open Angle Glaucoma.

- Sub-Investigator: INSURE Study (Novartis) –CAIN457C2302 A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppression.

- Sub-Investigator: SEATTLE/Acucela: 4429-202-A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hyrdrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry Age-Related Macular Degeneration (Geographic Atrophy).

- Principal Investigator: OCULOS: OHR-002-Phase 2 study of the efficacy and safety of Squalamine Lactate Ophthalmic Solution 0.2% twice daily in subjects with neovascular age-related macular degeneration.

- Sub-Investigator: REVIEW: Regeneron-VGFTe-AMD-1124
  An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration.

- Sub-Investigator: SAKURA DE-109:SANTEEN-32-007-A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye.

- Sub-Investigator: Eyegate (EGP-437-006)- A prospective, Multi-center, Randomized, Double-masked, Positive controlled, phase 3 clinical trial designed to evaluate the safety and efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution compared to Prednisolone Acetate Ophthalmic Supsepnsion (1%) in patients with non-infectious anterior segment uveitis. 2016-present

- Sub-Investigator: Peachtree (Clearside Biomedical)- A phase 3, Randomized, masked, controlled clinical trial to study the safety and efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the treatment of subjects with Macular Edema associated with non-infectious uveitis. 2016-2017

- Sub-Investigator: ACTHAR- An Open-label, multi-center, randomized, phase II study of the safety, and bioactivity of two dose regimens of subcutaneous injections of ACTH Gel in patients with non-infectious uveitis 2018-present

- Sub-Investigator: PANORAMA (VGFTe-OD-1411)- A phase 3, Double-masked, Randomized study of the efficacy and safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy. 2016-present

- Sub-Investigator: Iconic (IT-003)- A Phase 1, Open-Label, Multi-center study evaluating the safety and tolerability, Biologic activity, pharmacodynamics and pharmacokinetics of single and repeated escalating intravitreal doses of Icon-1 in patients with Uveal Melanoma who are planned to undergo Enucleation or Brachytherapy. 2016-2017

- Sub-Investigator: AURA (AU-011-201)- A prospective, randomized, multi-center, masked clinical trial designed to evaluate two doses of Light-Activated

AU-011 for the treatment of subjects with small to medium (1.5-4.0 mm thickness) Primary Uveal Melanoma. 2017-2018

- Sub-Investigator: Sapphire (CLS1003-301)- A randomized, masked controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal Aflibercept in subjects with Retinal Vein Occlusion. 2017-present

- Sub-Investigator: HAWK (RTH258-C001)- A two-year, Randomized, double-masked, multi-center, three-Arm study comparing the efficacy and safety of RTH258 versus Aflibercept in subjects with Neovascular Age-Related Macular Degeneration. 2015-2017.

- Sub-Investigator: Xcovery (X82-OPH-201)- A Randomized Double-Masked, Placebo-Controlled, Dose-Finding, Non-inferiority study of X-82 plus prn Eylea monotherapy in Neovascular AMD. 2015-2017.

- Sub-Investigator: Spectri (GX29185)- A Phase III, Multi-center, Randomized, Double-Masked, Sham-controlled study to assess the efficacy and safety of Lampalizumab Administered Intravitreally to patients with Geographic atrophy secondary to Age-Related Macular Degeneration. 2015-2018.

- Sub-Investigator: Omaspect (GX30191)- A multi-center, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with Geographic Atrophy secondary to Age-related macular Degeneration who have completed a Roche-Sponsored Study. 2017-2018

- Sub-Investigator: Proxima A (GX29633)- A multi-center, Prospective Epidemiologic study of the progression of Geographic atrophy secondary to Age-related macular Degeneration. 2016-2018

- Sub-Investigator: Aerpio/Time2B (AKB-9778-CI-5001)- A Phase 2, double-masked, Placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy. 2017-present

- Sub-Investigator: TLC399A2002- A Phase IIa Trial of TLC399 (ProDex) in subjects with Macular Edema due to Retinal Vein Occlusion (RVO): A double-masked, Randomized Trial to Evaluate efficacy and Tolerability 2017-present

- Sub-Investigator: Exposure (GX29455)- A Phase II, Multi-center, Randomized, Single-masked, sham injection-controlled exposure-response study of Lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with Geographic Atrophy 2016-2017

- Sub-Investigator: OLEi (GX28198)- A Multi-center, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab (FCFD4514S) in patients with Geographic Atrophy who have completed Genetech-sponsored lampalizumab Studies. 2017-2018

- Sub-Investigator: Cedar (AGN-150998)- A Multi-center, Double-masked, randomized 104-week, parallel-group, active-controlled study to evaluate the safety and efficacy of Abicipar Pegol in Treatment-naïve patients with Neovascular AMD. 2015-present

- Sub-Investigator: Avenue (BP29647)- A multi-center, multiple dose and regimen, randomized, active comparator controlled, double-masked, parallel-group, 36 week study to investigate the safety, tolerability, Pharmacokinetics and efficacy of R06867461 Administered Intravitreally in patients with Choroidal Neovascularization secondary to Age-Related Macular Degeneration. 2015-2017

- Sub-Investigator: Ladder (GX28228)- A Phase II, Multi-center, Randomized, Active Treatment-controlled study of the efficacy and safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in patients with Subfoveal Neovascular Age-Related Macular Degeneration 2015-present

- Sub-Investigator: Maple (1771-201-008)- A multi-center, open-label, single-arm study to evaluate Abicipar Pegol for Safety and Treatment effect in patients with Neovascular age-related macular degeneration (AMD) 2018-present

- Sub-Investigator: Stairway (CR39521)- Simultaneous Blockade of angiopoietin-2 and VEGF-A with the Bispecific antibody R06867461 (RG7716) for Extended Durability in the treatment of neovascular age-related macular degeneration. 2016-2017.

- Sub-Investigator: Boulevard (BP30099)- A multi-center, multiple dose, randomized, active comparator-controlled, double-masked, three parallel group 36-week study in patients with CI-DME. 2016-2017

- Sub-Investigator: Gilead- A Phase 2, randomized, Placebo-controlled trial evaluating the efficacy and safety of Filgotinib in subjects with active noninfectious uveitis. 2018-present

- Sub-Investigator: Opthea (OPT-302)- A dose-ranging study of intravitreal OPT-302 in combination with Ranibizumab in participants with Wet AMD. 2018-present

- Sub-Investigator: OPH2003B- A phase 2/3 randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreous administration of Zimura™ (Anti-C5 Aptamer) in subjects with Geographic Atrophy secondary to Dry Age-Related Macular Degeneration. 2018-present

- Sub-Investigator: OPH2007- A phase 2A open-label study to assess the safety of Zimura (Anti-C5) administered in combination with Lucentis 0.5mg in NVAMD. 2018-present

- Sub-investigator for Visudyne in Age-Related Macular Degeneration study (photodynamic therapy) 1999-2000.

- Sub-investigator for Miravant study of tin ethyl etiopurpurin (photodynamic therapy) 1999.

- Principal Investigator Phase 3 multicenter clinical trials of ISIS 2922 (fomivirsen sodium) intravitreal injection for therapy of cytomegalovirus retinitis (Isis Pharmaceuticals, Inc.), 1994-1998. This was the first controlled trial of an antisense drug for human use. FDA approval 1998; trade name Vitravene.

- GR40549: Sub-Investigator, A Multicenter, open-label extension stud to evaluate the long-term safety and tolerability of the Port Delivery System with Ranibizumab in patients with Neovascular Age-related macular denegation. 2018- Present

- GR40548: Sub-Investigator, A Phase III, multicenter, randomized, visual assessor-masked active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration. 2018- Present

- KHB-1801, Sub-investigator, A Multicenter, double-masked, randomized dose-ranging trial to evaluate the efficacy and safety of conbercept intravitreal injection in subjects with Neovascular age-related macular degeneration. 2018- Present

- CRTH258AUS04, Sub-Investigator, A Multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6 mg q 4 weeks compared to aflibcercept 2 mg q4 weeks in patients with neovascular age-related macular degeneration (nAMD) with persistent retinal fluid (MERLIN). 2018- present

- 010906IN, Sub-Investigator, Lumina: A Phase III, multicenter, sham-controlled, randomized, double-masked study assessing the efficacy and safety of intravitreal injections of 440 µg DE-109 for the treatment of active, non-infectious Uveitis of the Posterior Segment of the Eye. 2018-Present

- GR40844, Sub-investigator, A phase III, multicenter, randomized double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with Neovascular Age-Related Macular Degeneration (Lucerne). 2018-Present

- GR40349, Sub-investigator, A Phase III, Multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab (RO6867461) in patients with Diabetic Macular Edema (Yosemite). 2018-Present

- APL2-304, Sub-investigator, A Phase III, multicenter, randomized, double-masked, sham-controlled study to compare the efficacy and safety of Intravitreal APL-2 Therapy with Sham injections in patients with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). 2018-Present

- ADVM-022-02, Blood specimen collection study for the measurement of Adeno-Associated Virus (AAV) Neutralizing Antibodies in subjects with Neovascular (Wet) Age-related macular degeneration. 2018-Present

- ADVM-022-01, An open label Phase 1 study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-related macular degeneration (Optic). 2018-Present

- Gemini, Sub-investigator, A genetic screening and registry study to evaluate long-term clinical outcomes and disease progression in subjects with Non-central Geographic Atrophy (GA) who are carriers of high-risk genetic complement variants associated with Dry Age-related Macular Degeneration (AMD). 2019-present

- KSI-CL-102, Sub-Investigator, A phase 2, prospective randomized, double-masked, active comparator controlled, multi-center study to investigate the efficacy and safety of repeated intravitreal administration of KSI-301 in subjects with Neovascular (Wet) Age-related macular degeneration. 2019-Present

- ONS-5010-002, A Clinical effectiveness, multicenter, randomized, double-masked, controlled study of the efficacy and safety of ONS-5010 in Subjects with Subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). 2019- Present

- XBR1001, Sub-Investigator, A Phase III Double-blind, parallel group, multicenter study to compare the efficacy and safety of Xlucane versus Lucentis in Patients with Neovascular Age-Related Degeneration. 2019-Present

- GR40973, Sub-Investigator, A Phase II, multicenter, randomized, single-masked, sham-controlled study to assess safety, tolerability, and efficacy of intravitreal injections of FHTR2163 in Patients with Geographic atrophy secondary to age-related Macular Degeneration (Gallego). 2019-Present

- ALK-001, Sub-Investigator, A Phase 2/3 multicenter, randomized, double-masked, parallel-group, Placebo-controlled study to investigate the safety, Pharmacokinetics, tolerability, and efficacy of ALK-001 in Geographic Atrophy secondary to age-related macular degeneration. 2019-Present

- GR40550, Sub-Investigator, A Phase III, Multicenter, Randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the Port Delivery system with Ranibizumab in patients with Diabetic Macular Edema (Pagoda). 2019-Present.

- VGFTe(HD)-AMD-1905, Sub-Investigator, A randomized, single-masked, active-controlled Phase 2 study of the safety, tolerability, and efficacy of repeated doses of High-dose Aflibercept in patients with Neovascular Age-Related macular degeneration. 2019- Present.

- Collaborator for CPCRA Study 039: bis-POM for prophylaxis of cytomegalovirus retinitis, 1997-1999.

- Collaborator for HOE 901/3006 Human insulin analogue study (Hoechst Marion Roussel), 1997.

- Collaborator for ACTG 266 study of monoclonal antibody MSL 109 for adjunctive therapy of cytomegalovirus retinitis, 1996.

- Collaborator for study of oral ganciclovir for maintenance therapy of CMV retinitis (Syntex, Inc.), 1994-1996.

- Collaborator for ABCD Trial (Appropriate Blood Pressure Control in Diabetes Mellitus, Type II), 1996-1998.

- Collaborator for study of aminoguanidine in diabetic patients with nephropathy, 1995-1998.

- Collaborator for pilot study of irbesartan for kidney function in hypertensive diabetic patients, 1995-1998.

Additional Interests
Guitarist, Songwriting, Studio Recording, Skiing, Golf, Computers